Tiziana Life Sciences is trading at $1.02 (5.2%) up today, rebounding from a sharp 11.5% decline on August 3 as the market corrects for recent volatility.
- The stock is recovering from a significant drop in the previous session that occurred despite no clear news catalyst or fresh overnight announcements.
- Investors continue to weigh positive Phase 2 PET imaging data from July 31, which demonstrated reduced brain inflammation in multiple system atrophy (MSA) patients treated with intranasal foralumab.